AR098631A1 - METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCT - Google Patents
METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCTInfo
- Publication number
- AR098631A1 AR098631A1 ARP140104531A ARP140104531A AR098631A1 AR 098631 A1 AR098631 A1 AR 098631A1 AR P140104531 A ARP140104531 A AR P140104531A AR P140104531 A ARP140104531 A AR P140104531A AR 098631 A1 AR098631 A1 AR 098631A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- risk
- treating
- suffering
- bupropion
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001058 bupropion Drugs 0.000 title abstract 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 4
- 229960003086 naltrexone Drugs 0.000 title abstract 4
- 206010033307 Overweight Diseases 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 230000007211 cardiovascular event Effects 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 6
- 239000001115 mace Substances 0.000 abstract 6
- 230000002411 adverse Effects 0.000 abstract 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos cardiovasculares graves (MACE, major adverse cardiovascular events) en los sujetos, preferiblemente, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, que puedan tener sobrepeso o ser obesos. Composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos, con preferencia, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, en el cual el tratamiento reduce el riesgo de MACE. Reivindicación 1: Un método para tratar a un sujeto que tiene un riesgo de sufrir un evento adverso cardiovascular grave (MACE), caracterizado porque comprende los siguientes pasos: seleccionar a un sujeto que tenga un riesgo mayor de sufrir MACE para el tratamiento y administrar a dicho sujeto una cantidad de naltrexona o una de sus sales farmacéuticamente aceptables y bupropión o una de sus sales farmacéuticamente aceptables, eficaz para reducir el citado riesgo mayor.Compositions, kits, uses, systems and methods for using naltrexone and bupropion or their pharmaceutically acceptable salts, with the purpose of reducing the risk of developing cardiovascular events or adverse events, which includes serious cardiovascular adverse events (MACE) ) in the subjects, preferably, in those subjects whose risk of suffering adverse cardiovascular outcomes or MACE is greater, who may be overweight or obese. Compositions, kits, uses, systems and methods to use naltrexone and bupropion or their pharmaceutically acceptable salts, in the treatment of overweight or obesity in subjects, preferably, in those subjects whose risk of suffering adverse cardiovascular outcomes or MACE is greater , in which the treatment reduces the risk of MACE. Claim 1: A method of treating a subject that has a risk of suffering a serious cardiovascular adverse event (MACE), characterized in that it comprises the following steps: selecting a subject that has a higher risk of suffering MACE for treatment and administering to said subject an amount of naltrexone or one of its pharmaceutically acceptable salts and bupropion or one of its pharmaceutically acceptable salts, effective to reduce said higher risk.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098631A1 true AR098631A1 (en) | 2016-06-01 |
Family
ID=58700129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104531A AR098631A1 (en) | 2013-12-06 | 2014-12-05 | METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| ARP200103168A AR120476A2 (en) | 2013-12-06 | 2020-11-16 | METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103168A AR120476A2 (en) | 2013-12-06 | 2020-11-16 | METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR098631A1 (en) |
-
2014
- 2014-12-05 AR ARP140104531A patent/AR098631A1/en not_active Application Discontinuation
-
2020
- 2020-11-16 AR ARP200103168A patent/AR120476A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR120476A2 (en) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16057765A (en) | COMPOSITIONS AND METHODS TO REDUCE SERIOUS CARDIOVASCULAR ADVERSE EVENTS | |
| AR092177A1 (en) | METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST | |
| DOP2018000297A (en) | DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME | |
| CL2019000935A1 (en) | Pharmaceutical composition, methods for treatment and uses thereof. | |
| CL2018000222A1 (en) | New combination for use in cancer treatment | |
| CL2013000063A1 (en) | A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process. | |
| BR112015029056A2 (en) | compound, and subcutaneously implantable pharmaceutical pill or tablet to treat a human suffering from endometriosis | |
| AR101312A1 (en) | COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON | |
| CO7240377A2 (en) | Methods for the treatment of overweight and obesity | |
| AR124497A2 (en) | METHODS TO TREAT BINGE EATING OR COMPULSIVE EATING; USE OF BUPROPRION AND NALTREXONE TO PREPARE A MEDICATION FOR SUCH METHODS, AND PHARMACEUTICAL COMPOSITION | |
| AR095338A1 (en) | NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE | |
| BR112015027477A8 (en) | bolus, its uses, and kit | |
| AR111374A1 (en) | USE OF LIK066 IN PATIENTS WITH HEART FAILURE | |
| GT201700194A (en) | FORMULATION OF THEROPHENSIN AND BETABLOCKING COMBINATION | |
| BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
| CL2020002544A1 (en) | Ret inhibitor for use in treating cancer that has a ret alteration | |
| BR112018008697A2 (en) | method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination. | |
| CO2021004681A2 (en) | Use of reboxetine for the treatment of narcolepsy | |
| AR098832A1 (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
| CL2017000884A1 (en) | Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery | |
| ECSP12011951A (en) | USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR A PARASITARY DISEASE | |
| AR114030A1 (en) | PENTACYCLIC TRITERPENS IN THE TREATMENT OF AN ORAL-DENTAL PATHOLOGY | |
| AR098631A1 (en) | METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| AR097179A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FLUPIRTINE | |
| CL2019003288A1 (en) | A pharmaceutical combination for the treatment of cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |